Daliresp (roflumilast; AstraZeneca/Allergan/Takeda) is an oral phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of patients with severe chronic obstructive pulmonary disease (COPD), who suffer from chronic bronchitis and frequent exacerbations. PDE4 inhibitors are thought to relax airway smooth muscle, suppress the activation of inflammatory cells, and modulate the activity of pulmonary nerves. Daliresp received US and EU approvals for use in COPD in February 2011 and July 2010, respectively. In January 2011, Mitsubishi Tanabe announced that it had terminated its agreement with Nycomed, and would not pursue further development of roflumilast for respiratory diseases. As such, Datamonitor Healthcare does not forecast Daliresp to launch in Japan.
LIST OF FIGURES
9 Figure 1: Daliresp for COPD – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Daliresp for COPD
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Daliresp for COPD
13 Figure 4: Daliresp sales for COPD across the US and major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Daliresp drug profile
7 Table 2: Daliresp Phase III data in COPD
14 Table 3: Daliresp sales for COPD across the US and major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.